These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17314928)

  • 21. Do international model drug control laws provide for drug availability?
    University of Wisconsin Pain & Policy Studies Group
    J Pain Palliat Care Pharmacother; 2009; 23(2):145-52. PubMed ID: 19492215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Returned medicines: waste or a wasted opportunity?
    Mackridge AJ; Marriott JF
    J Public Health (Oxf); 2007 Sep; 29(3):258-62. PubMed ID: 17579236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ensuring palliative medicine availability: the development of the IAHPC list of essential medicines for palliative care.
    De Lima L; Krakauer EL; Lorenz K; Praill D; Macdonald N; Doyle D
    J Pain Symptom Manage; 2007 May; 33(5):521-6. PubMed ID: 17482041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of essential drugs. Eighth report of the WHO Expert Committee (including the revised Model List of Essential Drugs).
    World Health Organ Tech Rep Ser; 1998; 882():1-77. PubMed ID: 9922706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Making progress for how medicines are used in children.
    Taylor-Zapata P; Mattison DR
    Arch Pediatr Adolesc Med; 2007 Sep; 161(9):916; author reply 916-7. PubMed ID: 17768295
    [No Abstract]   [Full Text] [Related]  

  • 26. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights from the WHO and National Lists of Essential Medicines: Focus on Pediatric Diabetes Care in Africa.
    Rowlands A; Ameyaw E; Rutagarama F; Dipesalema J; Majaliwa ES; Mbogo J; Ogle GD; Chanoine JP
    Horm Res Paediatr; 2018; 90(2):82-92. PubMed ID: 30048982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
    AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twenty-five years of essential medicines.
    Quick JD; Hogerzeil HV; Velasquez G; Rago L
    Bull World Health Organ; 2002; 80(11):913-4. PubMed ID: 12481216
    [No Abstract]   [Full Text] [Related]  

  • 30. Essential medicines for children in Armenia.
    Kazaryan I; Vardanyan L
    Int J Risk Saf Med; 2015; 27 Suppl 1():S43-4. PubMed ID: 26639704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of essential drugs. Third report of the WHO Expert Committee.
    World Health Organ Tech Rep Ser; 1988; 770():1-63. PubMed ID: 3140500
    [No Abstract]   [Full Text] [Related]  

  • 32. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report.
    WHO Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2006; 937():1-461, back cover. PubMed ID: 16836287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidotes and their availability in South Africa.
    Wium CA; Hoffman BA
    Clin Toxicol (Phila); 2009 Jan; 47(1):77-80. PubMed ID: 18608270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of essential drug list in a rural secondary care hospital in south India with Indian & World Health Organization list 2011.
    Rao SG; Thomas D; Zachariah S; Kannan MS; Alvarez-Uria G
    Indian J Physiol Pharmacol; 2012; 56(4):375-81. PubMed ID: 23781658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [WHO program for prequalification of antiretroviral, antimalarial and antituberculosis drugs].
    Gross O
    Med Trop (Mars); 2006 Dec; 66(6):549-51. PubMed ID: 17286018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innovation and the WHO's essential medicines list: giving credit where credit is due.
    Wertheimer AI; Santella TM
    Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
    [No Abstract]   [Full Text] [Related]  

  • 37. The selection and use of essential medicines.
    World Health Organization
    World Health Organ Tech Rep Ser; 2011; (965):i-xiv, 1-249. PubMed ID: 22891532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Providing affordable essential medicines to African households: the missing policies and institutions for price containment.
    Tetteh Ek
    Soc Sci Med; 2008 Feb; 66(3):569-81. PubMed ID: 18023953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.